Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent
Connect Biopharma Holdings Ltd CNTB
$2.02
▼ -3.35%
($-0.07)
🗓️ Earnings Next Week
Open
$2.08
Prev Close
$2.09
Day Range
$1.99 – $2.12
52W Range
$1.23 – $3.82
Market Cap
$127.19M
Beta
-0.22
EPS (TTM)
$-1.15
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-03-19 |
| Shares Out. | 62,960,000 |
| Website | connectbiopharm.com ↗ |
| Phone | 18587271040 |
| Employees | 64 |
| Revenue | $169,000 |
| Gross Profit | $169,000 |
| Net Income | -$19.4M |
| Free Cash Flow | -$57.6M |
| Total Assets | $60.1M |
| Total Liabilities | $17.4M |
| Equity | $42.6M |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Connect Biopharma Holdings Ltd is a publicly traded company under the ticker symbol CNTB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)